Edgewise Therapeutics, Inc. $EWTX Shares Sold by Elmind Capital LP

Posted by Brenda Bartman on Jul 28th, 2026

Elmind Capital LP decreased its holdings in Edgewise Therapeutics, Inc. (NASDAQ:EWTX – Free Report) by 66.7% in the 1st quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 10,000 shares of the company’s stock after selling 20,000 shares during the quarter. Elmind Capital LP’s holdings in Edgewise Therapeutics were worth $315,000 as of its most recent filing with the SEC.

Other hedge funds and other institutional investors also recently modified their holdings of the company. Parallel Advisors LLC grew its holdings in shares of Edgewise Therapeutics by 64.9% in the 1st quarter. Parallel Advisors LLC now owns 1,032 shares of the company’s stock worth $33,000 after acquiring an additional 406 shares during the period. Canada Pension Plan Investment Board purchased a new stake in shares of Edgewise Therapeutics in the 2nd quarter worth about $45,000. Jones Financial Companies Lllp acquired a new stake in Edgewise Therapeutics in the 1st quarter valued at about $47,000. KBC Group NV purchased a new position in Edgewise Therapeutics during the 1st quarter valued at about $49,000. Finally, Seven Fleet Capital Management LP purchased a new position in shares of Edgewise Therapeutics during the 4th quarter worth approximately $50,000.

Analysts Set New Price Targets

EWTX has been the subject of a number of analyst reports. Truist Financial set a $52.00 price target on Edgewise Therapeutics in a report on Wednesday, May 6th. Oppenheimer started coverage on shares of Edgewise Therapeutics in a report on Thursday, July 9th. They issued an “outperform” rating and a $51.00 target price on the stock. Evercore reiterated an “outperform” rating and set a $55.00 price target on shares of Edgewise Therapeutics in a report on Monday, July 20th. Raymond James Financial reiterated a “strong-buy” rating and issued a $66.00 price target on shares of Edgewise Therapeutics in a report on Monday, June 1st. Finally, The Goldman Sachs Group lifted their price objective on Edgewise Therapeutics from $20.00 to $32.00 and gave the company a “neutral” rating in a research note on Wednesday, June 17th. One equities research analyst has rated the stock with a Strong Buy rating, eight have issued a Buy rating, one has issued a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average target price of $48.75.

View Our Latest Stock Analysis on EWTX

Insider Activity at Edgewise Therapeutics

In other Edgewise Therapeutics news, insider Alan J. Russell sold 200,000 shares of the company’s stock in a transaction on Wednesday, July 1st. The stock was sold at an average price of $39.41, for a total value of $7,882,000.00. Following the sale, the insider directly owned 24,555 shares in the company, valued at $967,712.55. This represents a 89.07% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, CMO Joanne M. Donovan sold 50,000 shares of the stock in a transaction dated Tuesday, May 5th. The stock was sold at an average price of $38.57, for a total transaction of $1,928,500.00. Following the sale, the chief marketing officer directly owned 4,367 shares in the company, valued at approximately $168,435.19. This represents a 91.97% decrease in their position. The disclosure for this sale is available in the SEC filing. Over the last quarter, insiders sold 255,230 shares of company stock worth $9,974,147. Corporate insiders own 21.30% of the company’s stock.

Edgewise Therapeutics Stock Up 1.9%

Shares of NASDAQ EWTX opened at $41.60 on Tuesday. The business has a fifty day simple moving average of $37.88 and a 200-day simple moving average of $33.13. Edgewise Therapeutics, Inc. has a 12 month low of $12.30 and a 12 month high of $48.40. The company has a market cap of $4.48 billion, a price-to-earnings ratio of -25.06 and a beta of 0.27.

Edgewise Therapeutics (NASDAQ:EWTX – Get Free Report) last issued its earnings results on Thursday, May 7th. The company reported ($0.46) earnings per share for the quarter, topping the consensus estimate of ($0.50) by $0.04. As a group, sell-side analysts expect that Edgewise Therapeutics, Inc. will post -2.01 EPS for the current fiscal year.

About Edgewise Therapeutics

(Free Report)

Edgewise Therapeutics, Inc (NASDAQ: EWTX) is a clinical-stage biopharmaceutical company headquartered in Cambridge, Massachusetts, focused on the discovery and development of precision medicines for the treatment of rare diseases. The company leverages its expertise in small-molecule chemistry and ion channel biology to address severe, unmet medical needs, particularly in the areas of kidney disorders and neuromuscular diseases.

At the core of Edgewise’s pipeline is EWTX-101, a novel, orally available inhibitor of TRPC5, a calcium channel implicated in nephrotic syndromes such as focal segmental glomerulosclerosis (FSGS) and other proteinuric kidney diseases.